HC Wainwright Issues Optimistic Outlook for VYGR Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Analysts at HC Wainwright raised their Q1 2025 EPS estimates for Voyager Therapeutics in a note issued to investors on Thursday, March 13th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.21) per share for the quarter, up from their previous estimate of ($0.30). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at ($1.47) EPS and FY2029 earnings at ($1.40) EPS.

VYGR has been the subject of a number of other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group reduced their target price on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday. Citigroup assumed coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target on the stock. Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the company an “overweight” rating in a research note on Wednesday. Finally, StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Voyager Therapeutics has a consensus rating of “Buy” and an average target price of $14.86.

Voyager Therapeutics Stock Down 4.2 %

Voyager Therapeutics stock opened at $3.90 on Monday. The stock has a 50-day moving average price of $4.83 and a 200 day moving average price of $5.82. The company has a market capitalization of $213.04 million, a price-to-earnings ratio of 5.49 and a beta of 0.99. Voyager Therapeutics has a 52 week low of $3.56 and a 52 week high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). The firm had revenue of $4.39 million for the quarter, compared to analyst estimates of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the prior year, the firm posted $1.25 EPS.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Erste Asset Management GmbH purchased a new stake in shares of Voyager Therapeutics during the third quarter worth approximately $6,192,000. Vestal Point Capital LP boosted its stake in Voyager Therapeutics by 151.0% during the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock worth $6,974,000 after purchasing an additional 740,000 shares during the last quarter. Farallon Capital Management LLC grew its holdings in shares of Voyager Therapeutics by 12.2% during the fourth quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock worth $14,576,000 after buying an additional 278,700 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Voyager Therapeutics by 24.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock valued at $7,828,000 after buying an additional 275,571 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Voyager Therapeutics in the fourth quarter worth about $746,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Insider Activity

In related news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 10,778 shares of company stock worth $58,548 in the last quarter. Corporate insiders own 4.53% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.